Treatment of Peyronie's disease with intralesional verapamil injection

Journal of Urology

Volumn 158, Issue 4, 1997, Pages 1395-1399

  Levine, Laurence A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Penile induration; Penis; Verapamil

Indexed keywords

ALPHA TOCOPHEROL; AMINOBENZOIC ACID; STEROID; VERAPAMIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COITUS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; HUMAN; INTRACAVERNOUS DRUG ADMINISTRATION; INTRALESIONAL DRUG ADMINISTRATION; MALE; PAIN; PENIS ERECTION; PEYRONIE DISEASE; PRIORITY JOURNAL; SEXUAL FUNCTION; SEXUAL INTERCOURSE; TREATMENT OUTCOME;

EID: 0030805933     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64224-1     Document Type: Article

References (35)

1. Levine, L. A., Merrick, P. F. and Lee, R. C.: Intralesional verapamil injection for the treatment of Peyronie's disease J. Urol., 151: 1522, 1994.
2. Mazo, V. E.: Nov metod za Ischenie na bolestta na Peironi. Khirurgiia, 42: 30, 1989.
3. Bellorofonte, C., Ruoppolo, M., Tura, M., Zaata, C., Tombolini, P., Menchini, T. and Fabris, G. F.: Possibilita di impiego del litotritore piezoelottrico nel trattamento delle fibrosi cavernose gravi. Arch. Ital. Urol. Nefrol. Androl., 61: 417, 1989.
4. Frank, I. N. and Scott, W. W.: The ultrasonic treatment of Peyronie's disease. J. Urol., 106: 83, 1971.
5. Scott, W. W. and Scardino, P. L.: New concept in treatment of Peyronie's disease. South. Med. J., 41: 173, 1948.
6. Gelbard, M. K., Dorey, F. and James, K.: The natural history of Peyronie's disease. J. Urol., 144: 1376, 1990.
7. Zarafonetis, C. J. D. and Horrax, T. M.: Treatment of Peyronie's disease with potassium para-aminobenzoate (Potaba). J. Urol., 81: 770, 1953.
8. Hasche-Klunder, R.: Zur Behandlung der Induration penis plastica mit para-aminobenzoesaurem Kalium (PABK). Urologe A., 17: 224, 1978.
9. Ralph, D. J., Brooks, M. D., Bottazzo, G. F. and Pryor, J. P.: The treatment of Peyronie's disease with tamoxifen. Brit. J. Urol., 70: 648, 1992.
10. Oosterlinck, W. and Renders, G.: Treatment of Peyronie's disease with procarbazine. Brit. J. Urol., 47: 219, 1975.
11. Morgan, R. J. and Pryor, J. P.: Procarbazine (Natulan) in the treatment of Peyronie's disease. Brit. J. Urol., 50: 111, 1978.
12. Akkus, E., Carrier, S., Rehman, J., Breza, J., Kadioglu, A. and Lue, T. F.: Is colchicine effective in Peyronie's disease? A pilot study. Urology, 44: 291, 1994.
13. Teasley, G. H.: Peyronie's disease: new approach. J. Urol., 71: 611, 1954.
14. Bodner, H., Howard, A. H. and Kaplan, J. H.: Peyronie's disease: cortisone-hyaluronidase-hydrocortisone therapy. J. Urol., 72: 400, 1954.
15. Winter, C. C. and Khanna, R.: Peyronie's disease: results with dermo-jet injection of dexamethasone. J. Urol., 114: 898, 1975.
16. Williams, G. and Green, N. A.: The non-surgical treatment of Peyronie's disease. Brit. J. Urol., 52: 392, 1980.
17. Morales, A. and Bruce, A. W.: The treatment of Peyronie's disease with parathyroid hormone. J. Urol., 114: 901, 1975.
18. Gelbard, M. K., Lindner, A. and Kaufman, J. J.: The use of collagenase in the treatment of Peyronie's disease. J. Urol., 134: 280, 1985.
19. Gelbard, M. K., James, K., Riach, P. and Dovey, F.: Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J. Urol., 149: 56, 1993.
20. Gustafson, H., Johansson, B. and Edsmyr, F.: Peyronie's disease: experience of local treatment with Orgotein. Eur. Urol., 7: 346, 1981.
21. Bartsch, G., Menander-Huber, K. B., Huber, W. and Marberger, H.: Orgotein, a new drug for the treatment of Peyronie's disease. Eur. J. Rheumatol. Inflam., 4: 250, 1981.
22. Verges, J. and Chateu, A.: Nouveau traitment de la maladie La Peyronie: la superoxyde desmutase par ionisations. Comparaison avec une serie ancienne classique. Ann. Urol., 22: 143, 1988.
23. Kelami, A.: Classification of congenital and acquired penile deviation. Urol. Int., 38: 229, 1983.
24. Levine, L. A. and Coogan, C. L.: Penile vascular assessment using color duplex sonography in men with Peyronie's disease. J. Urol., 155: 1270, 1996.
25. Kelly, R. B.: Pathways of protein secretion in eukaryotes. Science, 230: 25, 1985.
26. Aggeler, J., Frish, S. M. and Werb, Z.: Changes in cell shape correlate with collagenase gene expression in rabbit synovial fibroblasts. J. Cell Biol., 98: 1662, 1984.
27. Lee, R. C. and Ping, J. A.: Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J. Surg. Res., 49: 463, 1990.
28. Lee, R. C., Doong, H. and Jellema, A. F.: The response of burn scars to intralesional verapamil. Report of five cases. Arch. Surg., 129: 107, 1994.
29. 2+-channel blockers modulate metabolism of collagens within the extracellular matrix. Proc. Natl. Acad. Sci., 93: 5478, 1996.
30. Stetler-Stevenson, W. G.: Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Amer. J. Path., 148: 1345, 1996.
31. Wolf, J. S., Jr., Soble, J. J., Ratliff, T. L. and dayman, R. V.: Ureteral cell cultures II. Collagen production and response to pharmacological agents. J. Urol., 156: 2067, 1996.
32. Rodler, S., Roth, M., Nauck, M., Tamm, M. and Block, L. H.: Ca(2+)-channel blockers modulate the expression of interleukin-6 and interleukin-8 genes in human vascular smooth muscle cells. J. Mol. Cell Cardiol., 27: 2295, 1995.
33. Rehman, J., Benet, A. and Melman, A.: Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single blind study. J. Urol., part 2, 155: 633A, abstract 1289, 1996.
34. Teloken, C., Vaccaro, F., DaRos, C., Sogari, P. and Souto, C. A. V.: Objective evaluation of non-surgical approach for Peyronie's disease. J. Urol., part 2, 155: 633A, abstract 1290, 1996.
35. Schubert, G. E.: Anatomy and pathophysiology of Peyronie's disease and congenital deviation of the penis. Urol. Int., 47: 231, 1991.